You are here

Cell Therapy and Immunotherapy in AML

Antibody‐ and cell‐based immunotherapies have emerged as encouraging therapeutic approaches in applied hematology; however, a curative immunotherapy for acute myeloid leukemia (AML) remains undescribed, possibly due to the resistance of the leukemic stem cells (LSCs) that reside in several different fractions of the AML clone. In a recent STEM CELLS Translational Medicine concise review, researchers led by Peter Valent (Medical University of Vienna, Austria) discuss novel markers and targets expressed on LSCs in AML with an emphasis on the potential value of these antigens in the context of antibody‐based and/or cell‐based therapies. The authors also discuss various limitations and the possible pitfalls associated with such therapies.